These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 9416790

  • 1. Oral platinum analogue JM216, a radiosensitizer in oxic murine cells.
    van de Vaart PJ, Klaren HM, Hofland I, Begg AC.
    Int J Radiat Biol; 1997 Dec; 72(6):675-83. PubMed ID: 9416790
    [Abstract] [Full Text] [Related]

  • 2. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF, Koberle B, Masters JR, Kelland LR.
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Specificity of platinum-DNA adduct repair.
    Chaney SG, Vaisman A.
    J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
    [Abstract] [Full Text] [Related]

  • 6. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition.
    Amorino GP, Freeman ML, Carbone DP, Lebwohl DE, Choy H.
    Int J Radiat Oncol Biol Phys; 1999 May 01; 44(2):399-405. PubMed ID: 10760436
    [Abstract] [Full Text] [Related]

  • 7. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
    Raynaud FI, Odell DE, Kelland LR.
    Br J Cancer; 1996 Aug 01; 74(3):380-6. PubMed ID: 8695352
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.
    Rietbroek RC, van de Vaart PJ, Haveman J, Blommaert FA, Geerdink A, Bakker PJ, Veenhof CH.
    J Cancer Res Clin Oncol; 1997 Aug 01; 123(1):6-12. PubMed ID: 8996534
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
    van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, Beijnen JH, Bartelink H, Begg AC.
    Eur J Cancer; 1998 Jan 01; 34(1):148-54. PubMed ID: 9624250
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI, Boxall FE, Goddard P, Barnard CF, Murrer BA, Kelland LR.
    Anticancer Res; 1996 Jan 01; 16(4A):1857-62. PubMed ID: 8712713
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    O'Neill CF, Hunakova L, Kelland LR.
    Chem Biol Interact; 1999 Nov 15; 123(1):11-29. PubMed ID: 10597899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.